Navigation Links
African research identifies strong candidate for possible single-dose malaria cure

A recently discovered compound from the aminopyridine class not only has the potential to become part of a single-dose cure for all strains of malaria, but might also be able to block transmission of the parasite from person to person, according to a research collaboration involving the Medicines for Malaria Venture (MMV), based in Switzerland, and the Drug Discovery and Development Centre (H3-D) at the University of Cape Town, South Africa. On the basis of initial results it was selected by MMV for further development making it the first compound researched on African soil to enter preclinical development in partnership with MMV.

An African solution to save lives

Mrs Naledi Pandor, the Minister of Science & Technology, said: "This is a significant victory in the battle to alleviate the burden of disease in the subcontinent. Clearly the war on this disease is not yet won, but I am excited by the role that our excellent scientists have played in this milestone in finding a potential cure for malaria and possibly preventing its transmission. Congratulations to Professor Kelly Chibale and all involved. This is evidence of the world-class science being done in South Africa and the continent, and of the power of continental and international scientific collaboration in the multidisciplinary approaches that are essential in addressing the societal challenges of our time."

Dr Max Price, the Vice-Chancellor of UCT, said: "H3-D was founded at UCT in 2010 for this very purpose: to develop African expertise towards solving the health problems that beset the developing world. We trust this clinical candidate is the first of many contributions Professor Chibale and his team will be making to the advancement of international medicine."

H3-D identified a molecule, code named MMV390048, which was selected in July 2012 by MMV's Expert Scientific Advisory Committee for further development. The promising new compound shows potent activity against multiple points in the malaria parasite's lifecycle. This means it not only has the potential to become part of a single-dose cure for malaria but might also be able to block transmission of the parasite from person to person.

The aminopyridine series was initially identified by Griffith University scientists in Australia as part of MMV's extensive malaria screening campaign of around 6 million compounds. A team of scientists from H3-D, led by UCT Professor Kelly Chibale, further scrutinised and explored the antimalarial potential of the series. With parasitological, pharmacological and contract chemistry support from the Swiss Tropical and Public Health Institute (Switzerland), the Centre for Drug Candidate Optimization at Monash University (Australia) and Syngene (India) respectively, the H3-D team selected the most promising compounds from the series to be optimised and retested. In just 18 months the team had identified and developed a candidate suitable for preclinical development.

Equipping the next generation of African scientists

"We are very excited that this promising compound, researched by African scientists, has been selected by MMV for further development," said Professor Chibale, the Founder and Director of H3-D. "This is truly a proud day for African science and African scientists. Our team is hopeful that the compound will emerge from rigorous testing as an extremely effective medicine for malaria a disease that accounts for 24% of total child deaths in sub-Saharan Africa. What is more, H3-D and MMV achieved MMV390048 as a clinical candidate in record time. In the process we have developed a unique model for successful technology platforms, and generic modern pharmaceutical industry expertise and skills, to discover drugs in potentially any disease area in Africa."

Dr Tim Wells, MMV's Chief Scientific Officer, said: "This is a great achievement and an excellent example of the quality of research that can be fostered in Africa. We look forward to seeing more exciting compounds emerge from Kelly's team and are proud to be collaborating with H3-D; not only is it conducting excellent science today, but it is also providing world-class training for the next generation of African scientists."

What is so unique and exciting about MMV390048

It is very potent: it displayed a complete cure of animals infected with malaria parasites in a single dose given orally, and thus has the potential to cure millions of people.

It is active against a wide panel of resistant strains of the malaria parasite.

Developing the drug has made possible the training of more than 10 local scientists and cemented a strong relationship with an international partner.

The clinical candidate is in line to enter clinical trials in late 2013.


Contact: Jaya Banerjji
Medicines for Malaria Venture

Related biology news :

1. Levels of hepatitis C virus higher among African-Americans and males
2. South African daffodils may be a future cure for depression
3. Herbivores select on floral architecture in a South African bird-pollinated plant
4. African scientist, designer partner to fashion anti-malaria garment that wards off bugs
5. Treatment to benefit African infants at risk of endemic fever
6. UNH researchers find African farmers need better climate change data to improve farming practices
7. New method: Research team analyzes stress biology in babies
8. A mechanism providing clues for research into pancreatic diabetes is described
9. Behind closed doors: Researchers show how probiotics boost plant immunity
10. HALO: One-of-a-kind research aircraft ready for takeoff
11. Researchers develop method to grow artificial tissues with embedded nanoscale sensors
Post Your Comments:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced ... 29, 2015 at 11:00 a.m. Israel time, at ... 98 Yigal Allon Street, 36 th Floor, Tel Aviv, ... Eric Paneth and Izhak Tamir to the Board of ... as external directors; , approval of an amendment to certain terms ...
(Date:11/24/2015)... SAN FRANCISCO , Nov. 24, 2015 /PRNewswire/ ... today announced that Emily Leproust, Ph.D., Twist Bioscience ... Piper Jaffray Healthcare Conference on December 1, 2015 ... Palace Hotel in New York City. ... . Twist Bioscience is on ...
Breaking Biology Technology: